诱导化疗联合同期放化疗对比单纯同期放化疗治疗IVA-IVB期鼻咽癌的III期随机试验最终结果
BACKGROUND: Concurrent chemoradiotherapy (CCRT) is superior to radiotherapy alone for treating locoregionally advanced nasopharyngeal carcinoma (NPC). Whether adding induction chemotherapy (IC) further improves the outcome warrants investigation.…
要点
- 诱导化疗联合同期放化疗可显著改善IVA-IVB期鼻咽癌的5年无病生存率。
- 联合组骨髓抑制更常见,导致每周顺铂中断率更高。
- 总生存未获显著改善,需权衡毒性增加与DFS获益。
核心结论
- 在IVA和IVB期鼻咽癌患者中,MEPFL方案诱导化疗后行同期放化疗耐受性可接受,并显著改善无病生存,但总生存未改善。
研究设计与样本
- 开放标签多中心III期随机试验,在台湾11家机构开展,纳入IVA或IVB期鼻咽癌患者,随机分入诱导化疗联合同期放化疗组(239例)或单纯同期放化疗组(240例)。
主要发现
- 中位随访72.0个月后,联合组5年无病生存率为61%,单纯组为50%,风险比=0.739(95%CI 0.565-0.965),P=0.0264,分析时按N3b和LDH分层并调整T分期。
- 诱导化疗最常见毒性为白细胞减少(3级47%,4级12%)和血小板减少(3级24%,4级3%)。
- 放疗期间两组均以严重口腔黏膜炎为主要副作用,联合组骨髓抑制人数增加,因此中断每周顺铂者更常见。
关键数值与推荐
- 诱导化疗方案:3周期丝裂霉素C、表柔比星、顺铂和5-氟尿嘧啶/亚叶酸钙(MEPFL)。
- 放疗期间每周顺铂剂量为30 mg/m2。
- 放疗剂量:原发肿瘤总剂量70 Gy或以上,受累颈部66-70 Gy,每次1.8-2.2 Gy,每周5次。
临床怎么用
- 对于IVA和IVB期鼻咽癌患者,可考虑在同期放化疗前加用MEPFL诱导化疗以改善无病生存,但需密切监测骨髓抑制及顺铂中断风险。
- 因总生存未获益,临床决策应结合患者耐受性和个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Concurrent chemoradiotherapy (CCRT) is superior to radiotherapy alone for treating locoregionally advanced nasopharyngeal carcinoma (NPC). Whether adding induction chemotherapy (IC) further improves the outcome warrants investigation. PATIENTS AND METHODS: This open-label multicenter phase III trial was conducted at 11 institutions in Taiwan. Patients with stage IVA or IVB NPC were randomized to receive IC followed by CCRT (I-CCRT) or CCRT alone. Patients in the I-CCRT arm received three cycles of mitomycin C, epirubicin, cisplatin, and 5-fluorouracil/leucovorin (MEPFL). All patients received 30 mg/m2 cisplatin weekly during radiotherapy, which was delivered as 1.8-2.2 Gy per fraction with five daily fractions per week, to a total dose of 70 Gy or greater to the primary tumor and 66-70 Gy to the involved neck. The primary end point was disease-free survival (DFS). RESULTS: In this study, 240 and 239 patients were randomized to CCRT and I-CCRT arm, respectively. The most prominent toxicities of induction were leukopenia (grade 3 and 4: 47% and 12%) and thrombocytopenia (grade 3 and 4: 24% and 3%). During radiotherapy, severe mucositis was the major side-effect in both arms; an increased number of patients in the I-CCRT arm had myelosuppression; hence, discontinuation of weekly cisplatin was more common. After a median follow-up of 72.0 months, the I-CCRT arm had significantly higher DFS than that of the CCRT arm [5-year rate 61% versus 50%; hazard ratio=0.739, 95% confidence interval (CI)=0.565-0.965; P = 0.0264], after stratified for N3b and LDH, and adjusted for T stage. CONCLUSION: Induction with MEPFL before CCRT was tolerable and significantly improved the DFS of patients with stage IVA and IVB NPC though overall survival not improved. CLINICAL TRIAL INFORMATION: NCT00201396.
引用
- Hong RL, Hsiao CF, Ting LL, et al. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Ann Oncol. 2018. PMID: 30016391. doi:10.1093/annonc/mdy249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。